Physician profile
Franz P Rischard
NPI 1346272424
$54,655.82
in general payments reported to CMS, 2019-2025
8 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.46 · 2020: $4,040 · 2021: $1,829 · 2022: $1,902 · 2023: $12K · 2024: $15K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $4,961 · Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,640.00 |
| Travel and Lodging | $4,960.90 |
| Food and Beverage | $1,245.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47,762.00 | 2022-2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $4,755.03 | 2019-2025 | Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $1,700.00 | 2021 | |
| United Therapeutics Corporation | $348.76 | 2019-2025 | Remodulin, Orenitram |
| Johnson & Johnson Health Care Systems INC. | $66.27 | 2023-2024 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $23.76 | 2024 | Nucala |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franz Rischard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.